Is microRNA expression profile in prostate cancer dependent on clinicopathologic stage or cell subtype?

The identification of reliable prognostic and predictive biomarkers for monitoring prostate cancer remains an important research goal. Ideally, such biomarkers will transform clinical decision-making by providing clues to each individual patient’s disease aggressiveness, response to therapy, and risk of recurrence. Genomic approaches in early stage localized prostate cancer have been used for predicting treatment outcomes. One example of this type of genomic test is the Mi-Prostate Score (MiPS), which incorporates blood PSA levels and urinary levels of TMPRSS2-ERG and PCA3.